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Expert consensus holds that post-market, systematic surveillance of ICD leads is essential to 
ensure confirmation of adequate lead performance. GALAXY (NCT00836589) and CELESTIAL 
(NCT00810264) are ongoing multicenter, prospective, non-randomized registries conducted to 
confirm the long-term safety and reliability of Biotronik leads.  
Methods and Results 
ICD and CRT-D patients are followed for Linox and Linoxsmart ICD lead performance and safety 
for 5 years post-implant. All procedural and system-related adverse events (AEs) were assessed 
at each follow-up, along with lead electrical parameters.  An independent CEC of EPs 
adjudicated AEs to determine AE category and lead relatedness.  The analysis used categories of 
lead observations per ISO 5841-2 (Third edition).   
A total of 3,933 leads were implanted in 3,840 patients (73.0% male, mean age 67.0 ± 12.2 
years) at 146 US centers.  The estimated cumulative survival probability was 96.3% at 5 years 
after implant for Linox leads and 96.6% at 4 years after implant for Linoxsmart leads. A 
comparison of the Linox and Linoxsmart survival functions did not find evidence of a difference (p 
= 0.2155). The most common AEs were oversensing (23, 0.58%), conductor fracture (14, 
0.36%), failure to capture (13, 0.33%), lead dislodgement (12, 0.31%), insulation breach (10, 
0.25%), and abnormal pacing impedance (8, 0.20%).  
Conclusions 
Linox and Linoxsmart ICD leads are safe, reliable and infrequently associated with lead-related 
AEs.  Additionally, estimated cumulative survival probability is clinically acceptable and well 
within industry standards.  Ongoing data collection will confirm the longer-term safety and 
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Introduction 
In the three and one-half decades since its inception, implantable cardioverter-defibrillator 
(ICD) therapy has revolutionized the management of patients with or at risk for malignant 
ventricular arrhythmias and in the process has saved numerous patient lives.  Advances in ICD 
lead design have led to improvements in implant technique, reliability, extractability and clinical 
outcomes in patients with heart disease.  Some design changes, however, have led to clinically 
significant and highly publicized performance and patient safety issues (e.g., Sprint Fidelis 
(Medtronic, Minneapolis, MN, USA) and Riata leads (St. Jude Medical, Sylmar, CA, USA)).1-6  
Bench-top analysis is one means of assessing ICD lead performance, but lacks the myriad of 
‘real-world’ factors that might influence actual clinical performance (e.g., implant technique, 
patient and physician variables).  Product performance reports are another means of identifying 
ICD lead issues, but are typically based on analysis of voluntary product returns and are not 
necessarily subject to the scrutiny of systematic data collection and unbiased adjudication.  
Thus, they have a propensity for under-reporting of performance issues.  Expert consensus 
holds that post-market, systematic surveillance of ICD leads is essential to ensure confirmation 
of adequate lead performance; this must be independent of returned product, or lead approval 
and labeling evaluations.7-10 In 2008, in response to a congressional mandate, the FDA launched 
the ‘Sentinel Initiative’, which advocated active post market safety surveillance of (among other 
things) medical device technologies utilizing ‘secondary use’ protocols.11 To this end, the 
current study addresses ICD lead performance by prospective analysis of two large, multicenter 
prospective lead performance registries. 
 
The GALAXY (NCT00836589) and CELESTIAL (NCT00810264) registries are ongoing 
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term safety and reliability of Biotronik leads. These registries provide a means of evaluating 




The GALAXY registry is an ongoing multicenter, prospective, non-randomized, 5-year data 
collection registry designed to gather long-term safety and reliability data on Biotronik’s Linox 
family of ICD leads.  A total of 1,999 patients were enrolled at 98 United States (US) sites.  The 
institutional review board at each participating site approved the registry protocol.  Enrollment 
began in January 2009 and was completed in November 2011.  
 
The CELESTIAL post-approval registry is an ongoing multicenter, prospective, non-randomized, 
5-year data collection registry designed to gather long-term safety and reliability data on 
Biotronik’s Corox family of bipolar left ventricular pacing leads.   However, many CELESTIAL 
patients also have a Linox family ICD (right ventricular) lead implanted and these patients were 
included in the current study.  A total of 2,499 CELESTIAL patients were enrolled at 97 US sites, 
with 1,843 of these patients receiving a Linox family ICD lead on or after the start date of study 
data collection.  The institutional review board at each participating site approved the registry 
protocol.  Enrollment began in December 2008 and was completed in October 2013. 
 
A total of 3,933 Linox family ICD leads were implanted for both registries and all implanted 
leads and generators were Federal Drug Administration (FDA) approved and non-
investigational. Inclusion criteria for both registries required that patients were implanted with 
the study lead and a Biotronik generator.  GALAXY patients were enrolled within 1-45 days 
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CELESTIAL patients were enrolled 7-180 days post-successful study lead implant and were 
implanted with a Biotronik Cardiac Resynchronization Therapy Defibrillator (CRT-D) or Cardiac 
Resynchronization Therapy Pacemaker (CRT-P).  All CELESTIAL patients in the current analysis 
were implanted with a Linox family ICD lead connected to a Biotronik CRT-D generator.  
Additional inclusion criteria included patients being at least 18 years of age, able to understand 
the nature of the registry and provide informed consent, and being available for follow-up visits 
on a regular basis at the investigational site. 
 
Exclusion criteria at the time of enrollment for both registries included enrollment in an 
investigational device exemption (IDE) clinical study, planned cardiac surgical or interventional 
measures within the next 6 months, expected to receive a heart transplant within 1 year, life 
expectancy less than 1 year, presence of another life-threatening illness separate from their 
cardiac disorder, pregnancy, inability to provide data on the implanted system, demographics, 
and adverse events since implant.  
 
The Linox family of ICD leads is differentiated into Linox and Linoxsmart models. Biotronik first 
received FDA approval for the Linox ICD lead on January 27, 2006 and for the Linoxsmart ICD lead 
on September 17, 2010. As of December 31, 2014, the worldwide distribution for the ICD lead 
models represented in this study was 103,380 Linox and 67,490 Linoxsmart ICD leads.12 
 
All Linox family leads are implantable, transvenous ICD leads with dedicated sensing and pacing 
bipoles. The tip and ring electrodes are comprised of a platinum/iridium alloy base with a 
fractal iridium surface. The distal tip has a steroid-eluting collar, which contains up to 1.3 mg of 
dexamethasone acetate (DXA). All Linox family leads have one shock electrode that is positioned 
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additional proximal shock electrode for placement in the superior vena cava.  All Linox family 
leads have silicone insulation.  Linoxsmart models are additionally treated with a surface 
treatment, Silglide®.  Silglide® is a silicone-based surface treatment similar to the silicone 
based-tubing substrate, but made unique by a polymerization process that allows it to 
acquire a different chemical structure that is responsible for its improved gliding 
characteristics and reduced friction within the introducer sheath and between leads.   
 
All Linox family leads have a lead diameter of 7.8 F.  The pace/sense cable conductor is made of 
7x7 filars of MP35N® (a nickel-cobalt based proprietary alloy) material and the shock coil cable 
conductor is made of 7x7 filars of MP35N®/silver. The pace/sense and shock coil cable 
conductors are wrapped with a Teflon™ Perfluoroalkoxy (PFA) coating.  The inner conductor is 
a four filar wire conductor made of MP35N®. The Linox family has four cable lumens to provide 
a symmetric cross-sectional design.  A cross-section of a Linox family SD ICD lead is shown in 
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Figure 1:  Cross-section of Linox Family SD ICD Lead
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Table 1: Linox Family of ICD Leads 
Name Fixation Coils Insulation 
Linox S active single silicone 
Linox SD active dual silicone 
Linox T passive single silicone 
Linox TD passive dual silicone 
Linoxsmart S active single 
silicone with Silglide® surface 
treatment 
Linoxsmart SD active dual 
silicone with Silglide® surface 
treatment 
Linoxsmart TD passive dual 
silicone with Silglide® surface 
treatment 
 
Study design and data collection 
Patients were seen for in-office follow-up visits per the study site’s standard of care at the time 
of study start-up, typically every 3 or 4 months (the maximum study visit interval in this 
analysis is 6 months). Follow-up data collection included assessments of adverse events (AEs); 
collection of sensing, threshold, and impedance measurements for Biotronik leads; and 
collection of shock information.  This included the most recent shock impedance, charge time, 
and energy for Biotronik ICD leads. All interim device interrogations occurring at the site were 
required to be documented and have the same requirements as a study visit.  Data collected 
during remote monitoring visits were not used for these registries. 
 
The GALAXY and CELESTIAL registry protocols collected AEs related to the implanted system or 
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during or as a result of the implant procedure (e.g., cardiac perforation, hematoma, etc.). A 
‘system-related’ AE was considered to have occurred if both of the following conditions were 
met: 1) an event related to the implanted system occurred and 2) an action was taken to 
address the event (e.g., surgical intervention, lead pacing polarity or pacing mode 
reprogramming due to a suspected lead failure, lead abandonment and pacing disabled), or lead 
use was continued based on medical judgment despite a known clinical performance issue, 
which would have otherwise dictated action to be taken (e.g., patient too ill for intervention). 
 
An independent Clinical Events Committee (CEC) consisting of 5 electrophysiologists (EPs) was 
responsible for reviewing and adjudicating all AEs to classify the AE’s relatedness to the study 
lead and the AE category (i.e., lead dislodgement, potential conductor fracture, etc.).  Source 
documentation was collected on each protocol defined AE. Patient and site identifiers were 
redacted from the source documents provided to the CEC for adjudication. Two CEC members 
reviewed each AE.  If the two reviewers disagreed on the relatedness or category of the AE, the 
AE was also reviewed by the CEC chairperson or brought to a meeting of a quorum of committee 
members for discussion.  In the event of a full CEC committee review, each member voted and 
the majority vote was entered into the database as the final adjudication.    
  
The current analysis included AEs that the CEC adjudicated as being related to the Linox family 
ICD leads.  Additionally, one cardiac perforation occurring during ICD lead implant that was 
adjudicated as being related to the implant procedure was considered to be related to the Linox 
family ICD lead in this analysis. The analysis was performed using the categories of lead 
observations (i.e., cardiac perforation, conductor fracture, lead dislodgement, etc.) as defined 
in the third edition of the international standard ISO 5841-2.13  ISO 5841-2 is used by all cardiac 
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of leads. The standard provides descriptions for each of the lead observation categories:  
Conductor fracture was observed visually, electrically, or radiographically, and in some 
cases via returned lead analysis.  Failure to capture was intermittent or complete non-
capture or sudden or significant increase in pacing threshold.  Insulation breach was 
observed visually, electrically, or radiographically, and in some cases via returned lead 
analysis.  Pacing impedance was considered abnormal if a measurement was <200 Ω or 
>3000 Ω or there was a sudden or significant change in impedance, without evidence to 
corroborate conductor fracture or insulation breach.  In accordance with ISO 5841-2, the 
analysis excluded AEs that were resolved with successful lead repositioning.  This standard 
defines acute AEs as occurring within 30 days post-implant and chronic as occurring more than 
30 days post-implant. 
 
Statistical Analysis 
Kaplan-Meier actuarial graphs were created for the Linox and Linoxsmart ICD leads. The standard 
error (SE) for the estimated survival (freedom from AEs) was calculated using the method of 
Greenwood,14 and corresponding upper and lower confidence limits were calculated using the 
log-log transformation of Kalbfleisch and Prentice.15 All leads were assigned a censor or event 
date and status categorization per ISO 5841-2 (Third edition).13 For patients who were exited 
from the study for any reason (i.e., death, lost to follow-up, withdrawn) without a previous 
censor or event date, the patient’s study exit date was used as the lead’s censor date. Leads still 
in service without a previous censor or study exit date were assigned a March 23, 2015 censor 
date.  If a lead had more than 5 years of follow-up time, the lead was censored at 5 years.  The 
Linox and Linoxsmart survival function estimates were compared using a log-rank test (Mantel-
Haenszel).16 Age group survival functions were compared using a log-rank test (Mantel-
Haenszel) with a Sidak adjustment for multiple comparisons.  The age group at lead implant and 
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General tests of association were done comparing AE Event Categories using Fisher’s Exact 
(two-sided) Test.18   
 
Results  
Patient Population  
A total of 3,933 leads were implanted in 3,840 patients at 146 US centers. At enrollment, the 
patient population had a mean age of 67.0 ± 12.2 years old and a mean left ventricular ejection 




This article is protected by copyright. All rights reserved. 
15-JAN-16  Page 14 of 34 
 
Table 2. There were 570 (14.8%) patients with single chamber ICDs, 1,382 (36.0%) patients 
with dual chamber ICDs, and 1,888 (49.2%) patients with CRT-Ds. The median duration of 
follow-up was 3.6 years for Linox leads and 2.3 years for Linoxsmart leads. The implanted system 
history of all patients was reviewed and any patients with no record of prior devices and with 
the generator and all leads implanted on the same day were classified as de novo implants. 
There were 3,440 (89.6%) patients who received a de novo implant and 400 (10.4%) patients 
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Table 2: Patient Demographics  
Demographics 
Results 
n = 3,840 
Gender, n (%) 
  
Male 2,802 (73.0%) 
Female 1,038 (27.0%) 
  
  
NYHA, n (%) 
  
I 100 (2.6%) 
II 1,197 (31.2%) 
III 2,046 (53.3%) 
IV 100 (2.6%) 
Not Available or Not Reported 397 (10.3%) 
  
  
Venous Access (side), n (%) 
  
Left 3,661 (95.3%) 
Right 174 (4.5%) 
Not Reported 5 (0.1%) 
  
  




Subclavian 2,817 (73.4%) 
Axillary 586 (15.3%) 
Cephalic 256 (6.7%) 
Internal Jugular 1 (0.03%) 





Subclavian 133 (3.5%) 
Axillary 27 (0.7%) 
Cephalic 14 (0.4%) 
  
  
Not Reported 5 (0.1%) 
  
  
Race, n (%) 
  
White 2,594 (67.6%) 
Black or African American 460 (12.0%) 
Hispanic or Latino 433 (11.3%) 
Asian 50 (1.3%) 
Native Hawaiian or Other Pacific Islander 10 (0.3%) 
American Indian or Alaska Native 7 (0.2%) 
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Electrical Performance 
The overall lead electrical parameters (sensing, threshold, and impedance measurements) 
assessed at all study visits were within standard clinically acceptable values. The mean sensing 
value was 12.6 ± 5.46 mV for Linox leads and 13.2 ± 5.83 mV for Linoxsmart leads. The mean 
pacing threshold value at 0.5 ms pulse width was 0.6 ± 0.34 V for Linox leads and 0.6 ± 0.39 V 
for Linoxsmart leads.  The mean impedance was 560 ± 139.3 ohms for Linox leads and 556 ± 
132.3 ohms for Linoxsmart leads.  
 
Adverse Events 
There were 14 acute AEs in 14 leads (0.36% of all leads) and 91 chronic AEs reported in 91 
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Table 3 provides a summary of AEs. The most common acute AEs were cardiac perforation (6, 
0.15%), lead dislodgement (4, 0.10%), and failure to capture (2, 0.05%). The most common 
chronic AEs were oversensing (23, 0.58%), conductor fracture (14, 0.36%), failure to capture 
(13, 0.33%), lead dislodgement (12, 0.31%), insulation breach (10, 0.25%), and abnormal 
pacing impedance (8, 0.20%).  There were 52 additional AEs that were resolved with successful 
lead repositioning that were not included in this analysis per ISO 5841-2 (Third edition) (46 
lead dislodgements, 4 failures to capture, 1 oversensing AE immediately following implantation 
due to chatter with another lead, and 1 other AE in which lead was repositioned due to sub-
optimal superior vena cava (SVC) coil positioning).13    
 
The estimated cumulative survival probability is 96.3% at 5 years after implant for Linox leads 
and 96.6% at 4 years after implant for Linoxsmart leads.  A comparison of the Linox and Linoxsmart 




This article is protected by copyright. All rights reserved. 
15-JAN-16  Page 18 of 34 
 
Figure 2 displays a Kaplan-Meier actuarial graph of Linox and Linoxsmart ICD lead model groups. 
 
There were 41 AEs in the 1,933 leads implanted with a CRT-D system (2.12%) and 63 AEs in the 
2,000 leads implanted with dual or single chamber ICD (3.15%).  Leads implanted with CRT-D 
systems had a statistically significantly lower proportion of AEs than leads implanted with ICD 
systems (p=0.0470).  
 
There was no statistical difference between venous access method and the prevalence of AEs. 
For example, cephalic venous access accounted for 7.0% of all patients, and 6.9% of all AEs 
(p=1.000). Sub-group analysis of oversensing AEs, specifically, compared to venous access 
method used during the initial implant procedures for the Linox and Linoxsmart showed no 
statistically significant difference. For example, subclavian venous access was used in 73.9% of 
patients with lead oversensing AEs compared to 76.8% in the general population (p=0.8041).  
 
Gender did not influence lead performance: A comparison of the survival functions for all Linox 
family (Linox and Linoxsmart) leads between females and males was not statistically significant 
(p=0.3537), nor were comparisons between genders within the individual Linox models 
(p=0.8567) or Linoxsmart models (p=0.1049).  A comparison of the survival functions for all 
males with Linox leads and all males with Linoxsmart leads was not statistically significant 
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Figure 3 displays a Kaplan-Meier actuarial graph of Linoxsmart and Linox ICD model groups 
separated by gender.  There was also no statistically significant difference between or within 
AEs category according to gender (Table 3).   
 
There was no statistical difference between subject age at lead implant and the prevalence of 
AEs using the REPLACE DARE study age thresholds (p=0.5748).19 Additionally, there was no 
evidence of a difference in lead survival by DARE age group based on a log rank test of equality 
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Table 3: Adverse Event Details 
Adverse Events 
Results 
Total Male Female p-value* 
Chronic Events, n (%) 
       
Oversensing 23 (0.58%) 18 (0.63%) 5 (0.47%) 0.6462 
Conductor fracture 14 (0.36%) 11 (0.38%) 3 (0.28%) 0.7708 
Failure to capture 13 (0.33%) 9 (0.31%) 4 (0.38%) 0.7582 
Lead dislodgement 12 (0.31%) 8 (0.28%) 4 (0.38%) 0.7450 
Insulation breach 10 (0.25%) 5 (0.17%) 5 (0.47%) 0.1468 
Abnormal pacing impedance 8 (0.20%) 5 (0.17%) 3 (0.28%) 0.4535 
Abnormal defibrillation impedance 4 (0.10%) 2 (0.07%) 2 (0.19%) 0.2972 
Failure to sense (undersensing) 3 (0.08%) 3 (0.10%) 0 (0.00%) 0.5678 
Cardiac perforation 2 (0.05%) 1 (0.03%) 1 (0.09%) 0.4683 
Other 2 (0.05%) 1 (0.03%) 1 (0.09%) 0.4683 
Total 91 (2.31%) 63 (2.20%) 28 (2.63%) 0.4061 
        
Acute Events, n (%) 
       
Cardiac perforation 6 (0.15%) 3 (0.10%) 3 (0.28%) 0.3536 
Lead dislodgement 4 (0.10%) 2 (0.07%) 2 (0.19%) 0.2972 
Failure to capture 2 (0.05%) 2 (0.07%) 0 (0.00%) 1.0000 
Insulation breach 1 (0.03%) 1 (0.03%) 0 (0.00%) 1.0000 
Other 1 (0.03%) 0 (0.00%) 1 (0.09%) 0.2708 
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To our knowledge, this study represents the most extensive description of performance, safety 
and longevity of the Linox family of ICD leads published to date: It is large scale (n=3,933 leads), 
prospective in design, and incorporates a wide sampling of clinical sites (n=146) in both the 
academic and private practice arenas.  In addition, its results are buttressed by having all AEs 
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This study concludes that the performance of Linox and Linoxsmart ICD leads, as determined by 
electrical parameters is excellent:  Measures of sensing, impedance and pacing thresholds met 
or exceeded clinically acceptable values.  Further, this study validates that Linox and Linoxsmart 
ICD leads can be implanted safely with a low overall rate of acute AEs (0.36%) and a 
correspondingly low overall rate of chronic AEs (2.31%).  Finally, this study confirms the 
durability of Linox and Linoxsmart ICD leads, with an estimated cumulative survival probability of 
96.3% at 5 years for the Linox ICD leads and 96.6% at 4 years for the Linoxsmart leads.   
 
Comparisons With Other Studies 
The lead survival estimates for the Linox lead models in this study were within a comparable 
range to manufacturer product performance report (MPPR) values (96.3-97.4%) at 5 years for 
each lead.12 The lead survival estimates for the Linoxsmart lead models in this study were slightly 
lower than the range reported in the MPPR (97.8-98.9%) at 3 years, although the this study had 
longer-term follow-up than that reported in the MPPR.  This study found no significant 
difference in lead survivability between the Linox and Linoxsmart leads (p=0.2155). 
 
Few studies of ICD lead survival have included similar large numbers of ICD leads as the current 
study.  Reported ICD lead survival rates vary significantly between studies, but generally fall 
within a range of 85 -95% at 5 years.7-9,20-22  Disparities in study design, definitions of lead 
performance, patient characteristics, implant methodology and duration of follow-up among 
other variables confound direct comparisons between studies, manufacturers and specific lead 
models.  Nonetheless, the authors think that such comparisons are necessary to enhance the 
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 The Linox and Linoxsmart leads in this study demonstrated favorable lead survivability when 
compared to 4,078 Medtronic (Sprint family); Boston Scientific (Endotak family) and St. Jude 
(Riata & Durata family) ICD leads (93 – 97% estimated at 5 years) evaluated in a large-scale 
retrospective, single center study by Cohen et al.23 In addition, Linox and Linoxsmart leads had 
better survivability when compared to a University of Pittsburgh Medical Center study of 5,288 
Medtronic, Boston Scientific, or St. Jude Medical transvenous ICD leads as a whole (89.3% at 5 
years, with a mean follow-up of 3.7 years), and were similar to the single best individual lead 
survival rate reported in the same study (98.5%).22 
  
A pooled analysis of 3 large-scale, prospective SJM registries (OPTIMUM, SCORE and SJ4 PAS) 
evaluated 10,835 patients who received 11,016 SJM leads with Optim insulation (8,147 Durata 
and 2,869 Riata ST Optim) attached to a matched manufacturer ICD or CRT-D device found a 
mechanical failure- free survival rate of 99.0% (95% CI 98.4–99.3) at 5 years.24 Although this 
value seems significantly better than the lead survival values reported in the current study, it is 
important to distinguish that the SJM registry studies defined lead survival narrowly by strict 
mechanical criteria (i.e., failure of the structural integrity of the lead), whereas the current study 
incorporated broader, system-related AE criteria (e.g., lead dislodgment, oversensing, etc.) to 
determine lead survival.  If the current study were to include only those AEs with lead failures 
defined by mechanical criteria similar to the SJM registries, estimates of lead survivability for all 
Linox and Linoxsmart ICD leads in this study would increase to 99.1% (95% CI: 98.6,99.4) at 4 
years. 
 
Another pooled analysis of 4 prospective, SJM-sponsored studies (Advancements in ICD 
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Treatment for Heart Failure Management (RHYTHM), and the Post Approval Study (PAS) by 
Epstein et al. reported lead-related AE rates over a median follow-up of 22 months in 7,497 
patients with one of 27 different Riata model of leads: the individual and overall lead-related AE 
rates for conductor fracture, insulation damage, dislodgement, and perforation (<1% and 
1.41%, respectively) were comparable to those for the Linox and Linoxsmart ICD leads in the 
current study (<1% and 1.22%).25  These findings were also congruent with the results of the 
Porterfield et al. evaluation of 15,387 patients with SJM Riata leads (1500 and 7000 series 
models) followed over a mean of 18 months at 23 U.S. and 5 German sites, which showed 
similarly low individual (<1%) and overall (1.70%) AE rates.26 
 
A few studies, however, have called into question the performance of the Linox leads in 
particular.27,28,29  A recent British Columbian Cardiac Registry (BCCR) study suggested that these 
leads had a higher-than-expected rate of failure (3.4%) and lower-than-expected 5-year 
survivability (91.6%) at a median follow-up of 39-months as compared to Durata leads (SJM) 
(0.4% and 99.4%, respectively).27  Several significant and potentially confounding issues with 
the BCCR study exist that may help explain the differences in results compared to the current 
study:  First, the BCCR study had a relatively small sample size (n=477) of Linox ICD leads 
compared to the current study (n=2,935), and a disparate proportion of patients receiving Linox 
leads were not only reported to already have multiple leads in situ, but also to have had prior 
documentation of lead failures compared to the Durata group.  Thus, sampling bias may have 
negatively influenced the results for the Linox group. 
 
Another concern with the BCCR study is that the Linox lead patients predominately received a 
Medtronic ICD generator, while most Durata lead patients received a St. Jude Medical generator.  
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Biotronik). This is significant, since the vast majority (11/16 cases, or 69%) of “true lead 
failures” in the Linox group were attributed to high rate, non-physiological sensing for which no 
cause could be identified in 45% of the cases at the time of reoperation.  Medtronic 
(Minneapolis, MN) devices employ a proprietary Lead Integrity AlertTM (LIA) algorithm, which is 
sensitive to detecting non-physiologic intervals, short V-V sensing intervals (NPVVIs)—a factor 
that may have biased the Linox group toward AEs reporting in the BCCR study.  
 
It is also important to note that Medtronic ICD generators allow both integrated and true 
bipolar sensing configuration as a programming feature, an uncontrolled factor that may have 
influenced detection of NPVVIs.  In a study of randomly selected patients with Medtronic 
generators with LIA, Ng et al found that integrated bipolar lead sensing had a higher incidence 
of one component of the LIA, NPVVIs, without an associated higher rate of true lead 
malfunction.30  In fact, none of the patients with integrated bipolar lead sensing and NPVVIs 
demonstrated any clinical evidence of lead malfunction over a mean follow-up of 115.2 months.  
Moreover, the vast majority of patients with true bipolar lead sensing and NPVVIs (73%) 
exhibited no true lead failures over a mean follow-up of 86.5 months.  It is possible, therefore, 
that the Linox lead failures were significantly overestimated in the BCCR study by being 
connected to a Medtronic generator and that Durata lead failures might have been 
underestimated by not having been connected to Medtronic generators.  
 
Effects of Gender 
Important gender differences exist in the incidence, risk factors, and other clinical factors of 
women with heart disease.31-43  Clinical characteristics and ICD implant data of women tend to 
be different than those for men, with women typically being younger at age of ICD implant, 




This article is protected by copyright. All rights reserved. 
15-JAN-16  Page 27 of 34 
 
had ventricular fibrillation, and having lower defibrillation thresholds.43   Prior studies have 
suggested an increase in AEs among female patients implanted with ICD leads as compared to 
men, as well as higher rates of lead failure.20,44-46  This study analyzed the effect of gender on 
AEs and found no significant gender interaction.  Another similarly unique but encouraging 
finding of the current study was that measures of Linox and Linoxsmart lead performance and 
survivability were similar both between genders and between lead types within a gender. 
 
Effects of Age 
Younger patient age (especially pediatric) has been correlated with decreased ICD lead 
performance, increased AEs and poorer lead survivability when compared to older patients.20,47-
48 This correlation was not observed in the current study for Linox and Linoxsmart ICD leads: 
although it included only adult patients (≥18 years), there was no statistical difference between 
subject age at lead implant and the incidence of AEs (p=0.5748) or lead survivability (p=0.8946) 
using the REPLACE DARE study age thresholds. 
 
Conclusion 
Based on the results of this large-scale study, Linox and Linoxsmart ICD leads are safe, reliable and 
infrequently associated with lead-related AEs.  Additionally, intermediate-term (4-5 year) 
estimated cumulative survival probability is favorable, clinically acceptable and within industry 
standards.8-9,22,45   Ongoing data collection will confirm longer-term safety and performance of 
the Linox family of ICD leads. 
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